Financial Performance - The company reported a revenue of RMB 39.8 million for the year ended December 31, 2024, a decrease of 45.6% compared to RMB 73.2 million in 2023[9]. - Gross profit for the same period was RMB 23.9 million, down 50.8% from RMB 48.6 million in 2023, resulting in a gross margin of 59.9%[9]. - The loss attributable to shareholders was RMB 113.5 million, a slight improvement of 2.0% from RMB 115.8 million in the previous year[9]. - The adjusted loss per share based on non-Hong Kong Financial Reporting Standards was RMB 0.10, reflecting an 11.1% increase from RMB 0.09 in the previous year[9]. - The net loss for the year ended December 31, 2024, was RMB 1.153 billion, compared to a net loss of RMB 1.171 billion for the year ended December 31, 2023[37]. - Cash used in operating activities for the year ended December 31, 2024, was RMB 843 million, significantly impacted by high R&D, administrative, and sales expenses[38]. - Cash and cash equivalents decreased by 59.3% to RMB 54,607,000 from RMB 134,085,000 in 2023[10]. - Total assets decreased by 19.2% to RMB 463,060,000 from RMB 573,308,000 in 2023[10]. - The company's available distributable reserves as of December 31, 2024, amount to approximately RMB 418.1 million, a decrease from RMB 805.2 million in 2023[157]. Product Development and Innovation - The company’s caFFR system has over 95% accuracy and a convenient operation process taking less than five minutes, establishing its leading position in the domestic FFR measurement market[4]. - The caIMR system received approval from the National Medical Products Administration in April 2023, becoming the first commercially approved minimally invasive IMR measurement product globally[4]. - The company plans to expand the indications for the caFFR system to include acute STEMI, acute NSTEMI, and HFpEF patients, broadening its market reach[4]. - The company aims to launch an interventional surgical robot that integrates all clinical applications for automated PCI processes, enhancing clinical value[6]. - Future product launches include the caFFR system's expanded indications for acute STEMI, acute NSTEMI, and HFpEF patients, expected to be completed by 2025[24]. - The company has established a distribution network of 257 domestic distributors covering over 550 hospitals across 21 provinces in China[16]. - The production capacity is expected to support the annual production of 11,375 consoles and 1,130,765 pressure sensors[19]. - The company plans to integrate existing production and R&D facilities on a newly acquired land of approximately 20,000 square meters to enhance overall capabilities[19]. Corporate Governance and Board Structure - The board of directors is composed of three executive directors, three non-executive directors, and three independent non-executive directors, ensuring a balanced power structure[178]. - The company has appointed independent non-executive directors with extensive experience in financing and investment[70]. - The board's composition includes professionals with backgrounds in finance, law, and engineering, which supports a well-rounded strategic approach to business decisions[61][68]. - The company has established mechanisms to ensure independent viewpoints are provided to the board[194]. - The company has adopted corporate governance practices in line with the listing rules, ensuring high standards of governance to protect shareholder interests[177]. - The company has a diverse board with members holding degrees from prestigious institutions, including Tsinghua University and RMIT, ensuring a high level of expertise[60][66]. - The board diversity policy aims to enhance effectiveness by considering various diversity aspects, including gender, age, and professional qualifications[195]. - The company has achieved a gender ratio of 61% female employees and at least one female director on the board[196]. Financial Management and Risks - The company faces several major risks and uncertainties, some of which are beyond its control[85]. - The company has incurred significant operating losses since its inception and may continue to do so in the foreseeable future as it expands product development and seeks regulatory approvals for its pipeline products[88]. - The company may face challenges in recruiting patients for clinical trials, which could delay clinical development activities[91]. - Rising market prices for raw materials and components may adversely impact the company's financial condition[91]. - The company may face potential product liability claims, and its insurance may not be sufficient to cover all liabilities[91]. - The company actively communicates with stakeholders and aims to enhance operational management and sustainable development based on stakeholder feedback[98]. Employee and Director Management - The company aims to enhance employee skills through continuous education and training programs[49]. - The company has adopted a pre-IPO stock option plan to attract and retain skilled personnel for future growth and expansion[49]. - All directors actively participate in continuous professional development to enhance their knowledge and skills[198]. - The company maintains a proactive approach to director training and development to ensure compliance and effective governance[199]. - The term for executive directors is three years, with specific notice periods for termination outlined in service agreements[190]. - Independent non-executive directors are evaluated annually for their independence, ensuring they provide unbiased opinions[192]. Market Position and Strategy - The company aims to become a global leader in vascular interventional robotic surgery and a respected company worldwide[182]. - The company plans to continue expanding in both the Chinese and global markets to maximize shareholder value and will support capital expenditures through various financing channels[48]. - The company has established partnerships with various investment entities, including Shenzhen Tongchuang Weiye, which holds approximately 96.3% partnership interest in Tongxiang Haoguan[129]. - The company is indirectly owned by Ping An Group, which holds 100% of Ping An Capital and 72,000,000 shares in Ping An Investment[131]. Compliance and Legal Matters - The group has established compliance policies and procedures to ensure adherence to applicable laws and regulations, with no significant non-compliance events reported during the reporting period[165]. - There are no significant legal proceedings or arbitrations involving the company as of December 31, 2024[166]. - The independent auditor for the year ending December 31, 2024, is Shinewing (HK) CPA Limited, which has been appointed for the upcoming annual general meeting[151]. Shareholder Information - As of December 31, 2024, the total number of issued shares is 1,167,799,000[122]. - The top five customers accounted for 49.8% of the total revenue for the year ending December 31, 2024, compared to 43.8% in 2023[163]. - The largest single customer represented 22.1% of the total revenue for the year ending December 31, 2024, up from 14.2% in 2023[163]. - The company has a significant shareholder structure, with Shanghai Jinglin Equity Investment Management holding approximately 5.05% of the shares[127]. - The company has not reported any significant changes in its main business activities during the reporting period[80].

Financial Performance - Revenue decreased by approximately 46.6% from RMB 504 million for the six months ended June 30, 2023, to RMB 268 million for the six months ended June 30, 2024[3]. - Gross profit fell by about 49.9% from RMB 373 million for the six months ended June 30, 2023, to RMB 187 million for the same period in 2024, with a gross margin decline from 74.0% to 69.5%[4]. - The company recorded a loss of RMB 427 million for the six months ended June 30, 2024, compared to a loss of RMB 480 million for the same period in 2023[10]. - Net cash used in operating activities was RMB 412 million for the six months ended June 30, 2024, primarily due to significant R&D, administrative, and sales expenses[11]. - The company reported a basic and diluted loss per share of RMB 0.04, unchanged from the previous year[55]. - The loss attributable to shareholders for the six months ended June 30, 2024, was RMB 41,646,000, compared to RMB 47,479,000 for the same period in 2023, representing a decrease of approximately 12.4%[87]. Expenses and Cost Management - Research and development expenses decreased by approximately 18.3% from RMB 226 million for the six months ended June 30, 2023, to RMB 185 million for the same period in 2024[5]. - Sales expenses reduced by about 22.9% from RMB 384 million for the six months ended June 30, 2023, to RMB 296 million for the same period in 2024[6]. - General and administrative expenses decreased significantly from RMB 373.21 million for the six months ended June 30, 2023, to RMB 233.56 million for the six months ended June 30, 2024, representing a year-on-year decline of approximately 37.4%[8]. - Employee benefit expenses dropped by RMB 122.01 million, primarily due to a reduction in salaries and administrative staff[8]. - The company is focusing on cost control measures to manage expenses effectively amid declining sales[6]. Revenue Sources and Market Performance - FlashPressure caFFR pressure sensor sales dropped from RMB 40.6 million in 2023 to RMB 21.1 million in 2024[3]. - FlashAngio caFFR system sales decreased significantly from RMB 3.9 million in 2023 to RMB 15,000 in 2024[3]. - The company reported a total of RMB 308,000 in installation and training service revenue for the six months ended June 30, 2024, down from RMB 439,000 in 2023[3]. - Revenue from product sales dropped to RMB 26,560 thousand, down 46.8% from RMB 49,935 thousand year-over-year[74]. - Revenue from the Chinese market was RMB 26,497 thousand, a significant decline of 47.4% from RMB 50,366 thousand in the same period of 2023[77]. Research and Development - The R&D team consists of over 100 members, accounting for approximately one-third of the total workforce, focusing on innovative products in precision intervention therapy[22]. - The company continues to focus on research and development, particularly in the areas of coronary artery disease and related technologies[118]. - The proprietary consumables for the caFFR system have patient self-pay prices ranging from RMB 10,200 to RMB 12,000 in 33 provinces and regions, with 24 provinces including it in medical insurance reimbursement lists[21]. - The company is actively working to include the caIMR system's proprietary consumables in medical insurance reimbursement lists[21]. Corporate Governance and Shareholding - The board of directors consists of three non-executive directors, three independent non-executive directors, and three executive directors, ensuring a balanced distribution of power and authority[33]. - The company has adopted the corporate governance code and has complied with all provisions except for the separation of roles between the chairman and CEO, which is currently held by the same individual[33]. - As of June 30, 2024, Mr. Huo Yunfei holds 214,749,000 shares, representing approximately 18.39% of the company[39]. - The total shareholding of major shareholders indicates a significant concentration of ownership, with the top three shareholders holding over 50% of the shares[42][43]. - The company is subject to regulatory disclosures under the Securities and Futures Ordinance, ensuring transparency in shareholding[41]. Assets and Liabilities - Total assets increased to RMB 600,794 thousand as of June 30, 2024, compared to RMB 573,308 thousand on December 31, 2023, representing an increase of approximately 4.3%[57]. - Current liabilities surged to RMB 108,543 thousand, a significant increase from RMB 40,982 thousand, reflecting a rise of approximately 164.5%[58]. - The company recorded a total equity of RMB 480,257 thousand as of June 30, 2024, down from RMB 520,012 thousand, representing a decrease of about 7.6%[58]. - The company's total liabilities reached RMB 120,537 thousand, up from RMB 53,296 thousand, indicating a significant increase of approximately 126.3%[58]. Strategic Plans and Market Expansion - The company plans to continue expanding in the Chinese and global markets, focusing on product development and growth through internal development, mergers, and acquisitions[16]. - The company aims to enhance its competitive advantage in the FFR and IMR fields, expand IVD product coverage, and penetrate both domestic and overseas markets to achieve healthy growth and high-quality development in 2024[31]. - The company is exploring opportunities for mergers and acquisitions to strengthen its market position[120]. Compliance and Regulatory Matters - The company is committed to ensuring compliance with local regulations and standards[120]. - The company is subject to the Securities and Futures Ordinance of Hong Kong[120]. - The company has maintained a policy of regularly monitoring liquidity risks and ensuring sufficient cash and cash equivalents to meet its operational needs[71].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任 何聲明，並明確表示，概不就因本公告的全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 1 Rain Med Rainmed Medical Limited 潤邁德醫療有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2297） 有關截至2023年12月31日止年度的 年度報告補充公告 茲提述潤邁德醫療有限公司（「本公司」，連同其附屬公司統稱「本集團」）於2024年4月29日 刊發截至2023年12月31日止年度的年度報告（「2023年年報」）。除文義另有所指外，本公告 所用詞彙與2023年年報所界定者具有相同涵義。 本公司謹此就全球發售所得款項淨額約78.6百萬港元（「所得款項淨額」）於2023年12月31日 前的用途提供進一步資料。下表載列所得款項淨額擬定用途及其截至2023年12月31日的動 用情況概要： | --- | --- | --- | --- | --- | --- | |----------------------------------------------- ...

Financial Performance - Revenue for the six months ended June 30, 2024, was RMB 26.9 million, a decrease of 46.6% compared to RMB 50.4 million in the same period of 2023[1] - Gross profit for the same period was RMB 18.7 million, down 49.9% from RMB 37.3 million, resulting in a gross margin of 69.5%, compared to 74.0% in 2023[1] - The adjusted loss attributable to shareholders for the six months ended June 30, 2024, was RMB 40.2 million, a decrease of 4.5% from RMB 42.1 million in 2023[1] - Operating loss for the six months was RMB 44.7 million, compared to RMB 55.3 million in the same period last year[2] - The company reported a net loss of RMB 42.7 million for the period, compared to a net loss of RMB 48.0 million in 2023[2] - The company reported a loss attributable to shareholders of RMB 41,646 thousand for the six months ended June 30, 2024, compared to a loss of RMB 47,479 thousand for the same period in 2023, representing a decrease of approximately 12.9%[22] - The basic loss per share remained at RMB 0.04 for both the six months ended June 30, 2024, and 2023, indicating no change in performance on a per-share basis[22][23] - The loss for the six months ended June 30, 2024, was RMB 42.7 million, an improvement from a loss of RMB 48.0 million for the six months ended June 30, 2023[53] Revenue and Sales - Revenue for the six months ended June 30, 2024, was RMB 26,868 thousand, a decrease of 46.7% compared to RMB 50,374 thousand for the same period in 2023[11] - Product sales accounted for RMB 26,560 thousand, down 46.8% from RMB 49,935 thousand in the previous year[11] - Revenue decreased from RMB 50.4 million for the six months ended June 30, 2023, to RMB 26.9 million for the six months ended June 30, 2024, representing a year-on-year decline of approximately 46.6%[34] Expenses and Costs - Research and development expenses for the period were RMB 18.5 million, down from RMB 22.6 million in the previous year[2] - Employee benefit expenses decreased to RMB 45,550 thousand, down 30.3% from RMB 65,347 thousand in the same period last year[16] - Sales expenses decreased by approximately 22.9% to RMB 29.6 million for the six months ended June 30, 2024, from RMB 38.4 million for the same period in 2023, mainly due to reduced employee benefits and marketing development expenses[48] - General and administrative expenses significantly decreased by approximately 37.4% to RMB 23.4 million for the six months ended June 30, 2024, from RMB 37.3 million for the same period in 2023, primarily due to a reduction in employee benefits[50] Assets and Liabilities - Total assets as of June 30, 2024, amounted to RMB 600.8 million, an increase from RMB 573.3 million as of December 31, 2023[5] - Cash and cash equivalents were RMB 117.9 million, down from RMB 134.1 million at the end of 2023[5] - Trade receivables increased to RMB 7,831 thousand as of June 30, 2024, from RMB 3,691 thousand as of December 31, 2023, reflecting a growth of approximately 112.9%[25] - The net amount of trade and other receivables rose to RMB 17,698 thousand as of June 30, 2024, compared to RMB 10,350 thousand as of December 31, 2023, marking an increase of about 71.3%[25] - Trade payables decreased to RMB 1,552 thousand as of June 30, 2024, from RMB 3,447 thousand as of December 31, 2023, a decline of approximately 54.9%[31] - The company had a debt balance of RMB 25.5 million as of June 30, 2024, with unused bank financing of RMB 480.1 million[56] Corporate Governance - The company has adhered to all provisions of the corporate governance code, except for the deviation regarding the roles of the Chairman and CEO being held by the same individual, Mr. Huo Yunfei[61] - The Audit Committee, consisting of three independent non-executive directors, has reviewed the unaudited interim financial information for the six months ending June 30, 2024[64] - The company is committed to maintaining high standards of corporate governance to enhance shareholder value and accountability[61] - The company will continue to review and monitor its corporate governance practices to ensure compliance with the corporate governance code[61] - The company has established a standard code for securities trading by directors, which all directors confirmed compliance with during the reporting period[61] - The company has a diverse board composition, ensuring a balanced distribution of power and authority[61] Research and Development - The company continues to invest in the research, development, and commercialization of medical devices related to caFFR systems, caIMR systems, and IVD products[7] - The caFFR system has achieved over 95% accuracy and a convenient operation process of less than five minutes, establishing itself as a leading FFR measurement product in the domestic market[32] - The caIMR system received approval from the National Medical Products Administration in April 2023, becoming the world's first minimally invasive IMR measurement product approved for commercialization[32] - The company plans to expand the indications for the caFFR system to include acute STEMI, acute NSTEMI, and HFpEF patients, enhancing its product offerings[32] - The Flash Robot vascular interventional navigation surgical system is currently in the research and refinement stage, with successful animal trials completed in February 2022[42] - The company has obtained 85 II-class registration certificates for biochemical diagnostic reagents, covering major diagnostic categories such as liver function and kidney function[43] Market Strategy and Expansion - The company aims to enhance its competitive advantage in the FFR and IMR fields and expand its IVD product coverage and market presence in the second half of the year[44] - The company is actively pursuing overseas market layouts and strengthening domestic market penetration to achieve healthy growth and high-quality development in 2024[44] - The company plans to continue expanding in both China and global markets, focusing on product development and growth through internal development, mergers, and acquisitions[57] - As of June 30, 2024, the company has established a distribution network of 185 domestic distributors covering over 350 hospitals across 21 provinces, four autonomous regions, and four municipalities in China[34] - The company has sold and installed core products in over 700 hospitals, with more than 1,400 hospitals having used the core products in China[34] Other Financial Information - The company did not declare any interim dividend for the six months ended June 30, 2024[1] - The company has not declared or paid any dividends for the six months ended June 30, 2024, and 2023[29] - Other income increased from RMB 1.5 million for the six months ended June 30, 2023, to RMB 7.3 million for the six months ended June 30, 2024, primarily due to increased government subsidies[51] - Income tax expense changed from a credit of RMB 0.5 million for the six months ended June 30, 2023, to an expense of RMB 0.3 million for the six months ended June 30, 2024, mainly due to profit generated from interest income[52] - The company has capital commitments of RMB 283.7 million related to construction and services for its industrial park as of June 30, 2024[57]

Rainmed Medical Limited 潤邁德醫療有限公司 （於開曼群島註冊成立的有限公司） (Incorporated in the Cayman Islands with limited liability) Stock Code 股份代號 : 2 2 9 7 ANNUAL REPORT 年度報告 ANNUAL REPORT 2023 年度報告 R ain m e d M e dic al Limit e d 潤 邁 德 醫 療 有 限 公 司 目錄 | | | 公司資料 3 財務摘要 5 管理層討論及分析 7 董事及高級管理層 20 董事會報告 27 企業管治報告 50 獨立核數師報告 68 綜合損益表 74 綜合損益及其他全面收益表 75 綜合財務狀況表 76 綜合權益變動表 78 綜合現金流量表 80 綜合財務報表附註 82 財務概要 152 釋義 153 2023年環境、社會及管治報告 158 公司簡介 概況 我們於2014年成立，致力成為全球領先的血管介入手術機器人公司，目前專注於基於冠狀動脈造影的血流儲備 分數系統（「caFFR系統」）及基於冠狀動脈造影的微血管阻力指數系統（「caIM ...

Financial Performance - Revenue for the year ended December 31, 2023, was RMB 73.2 million, a decrease of 12.4% compared to RMB 83.6 million in 2022[2] - Gross profit was RMB 48.6 million with a gross margin of 66.3%, down from RMB 69.8 million and 83.5% in the previous year, representing a decline of 30.4%[2] - Loss attributable to shareholders was RMB 115.8 million, significantly improved from a loss of RMB 1,346.0 million in 2022, marking a 91.4% reduction[2] - Adjusted loss attributable to shareholders under non-Hong Kong Financial Reporting Standards was RMB 108.3 million, compared to RMB 100.9 million in 2022, an increase of 7.4%[2] - Basic and diluted loss per share was RMB (0.10), a substantial improvement from RMB (1.50) in the previous year, reflecting a 93.3% decrease in loss per share[2] - Total revenue for the year ended December 31, 2023, was RMB 73,219,000, a decrease of 12.4% from RMB 83,604,000 in 2022[36] - Revenue from product sales was RMB 72,684,000, down from RMB 82,634,000, representing a decline of 12.1%[36] - Revenue from installation and training services decreased to RMB 535,000 from RMB 970,000, a drop of 44.8%[36] - The company recorded a loss of RMB 1,171.0 million for the year ended December 31, 2023, compared to a loss of RMB 1,346.0 million for the year ended December 31, 2022[120] Assets and Liabilities - Total assets as of December 31, 2023, were RMB 573.3 million, down from RMB 690.3 million in 2022[27] - Cash and cash equivalents totaled RMB 134.1 million, with bank deposits maturing in over three months amounting to RMB 65.6 million[24] - Trade receivables increased to RMB 3,691,000 for the year ended December 31, 2023, up from RMB 148,000 in 2022, indicating improved collection efficiency[74] - The net amount of trade and other receivables rose to RMB 10,350,000 in 2023 from RMB 6,534,000 in 2022, showing a growth of approximately 58%[74] - Trade and other payables decreased to RMB 29,029,000 in 2023 from RMB 39,229,000 in 2022, indicating improved cash flow management[88] - The company has unutilized bank financing of RMB 490.0 million as of December 31, 2023[124] - Capital commitments amounted to RMB 356.0 million as of December 31, 2023, related to the purchase of construction and equipment services for the group's production facilities[125] Research and Development - Research and development expenses for the year were RMB 41.3 million, slightly down from RMB 44.2 million in 2022[5] - The company has developed 173 approved patents and 137 pending patents, with a dedicated R&D team of over 100 members[94] - The company aims to enhance its competitive advantage in the FFR and IMR fields and expand its IVD product coverage and market presence in 2024[105] - The company is committed to adhering to the Good Manufacturing Practice (GMP) standards for its medical products[158] - The company emphasizes the importance of clinical trials to validate the efficacy and safety of its medical devices[180] Product Development and Market Strategy - The company is engaged in the research, development, manufacturing, and commercialization of medical devices related to caFFR systems, caIMR systems, and IVD products in China, Europe, and other regions[33] - The company’s caFFR system has achieved over 95% accuracy and a convenient operation process of less than five minutes, establishing itself as a leading FFR measurement product in China[90] - The caIMR system received approval from the National Medical Products Administration in April 2023, marking it as the world's first minimally invasive IMR measurement product to complete confirmatory clinical trials[90] - The company plans to expand the indications for the caFFR system to include acute STEMI, acute NSTEMI, and HFpEF patients, enhancing its market reach[90] - The company aims to automate the entire PCI process through the integration of its vascular intervention robot with its existing clinical applications[90] - The company has halted clinical trials for the Flash RDN system, indicating a strategic shift in product development[96] Governance and Corporate Structure - The company has established an audit committee consisting of three independent non-executive directors to oversee financial reporting and internal controls[148] - The board of directors consists of executive directors including Mr. Huo Yunfei, Mr. Lv Yonghui, Mr. Zhang Liang, and Ms. Gu Yang, along with non-executive directors and independent non-executive directors[200] - The company is focused on enhancing corporate governance in accordance with the Corporate Governance Code[161] - The presence of multiple executive and independent directors suggests a robust governance framework[200] - The company is committed to transparency and accountability in its operations as reflected in the board's composition[200] Future Outlook - The company plans to continue expanding in both the Chinese and global markets, focusing on product development and potential mergers and acquisitions[137] - The company aims for healthy growth and high-quality development in 2024 despite a challenging industry landscape[105] - Future communications may include detailed financial performance and strategic initiatives as the company progresses[200]

Rainmed Medical Limited 潤邁德醫療有限公司 R ain m e d （於開曼群島註冊成立的有限公司） (Incorporated in the Cayman Islands with limited liability) Stock Code 股份代號 : 2 2 9 7 INTERIM REPORT 中期報告 INTERIM REPORT 2023 中期報告 M e dic al Limit e d 潤 邁 德 醫 董事會 執行董事 霍雲飛先生 （主席兼首席執行官） 呂永輝先生 （聯席首席執行官） 張亮先生 （首席財務官） 谷陽女士 （副總裁） 療 有 限 公 司 目錄 | 2 | 公司資料 | | --- | --- | | 4 | 財務摘要 | | 12 | 管理層討論與分析 | | 17 | 企業管治及其他資料 | | 29 | 中期簡明綜合收益表 | | 30 | 中期簡明綜合全面收益表 | | 31 | 中期簡明綜合資產負債表 | | 33 | 中期簡明綜合權益變動表 | | 35 | 中期簡明綜合現金流量表 | | 36 | 中期簡明綜合財務資料附註 | | 61 | 釋 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任 何責任。 Rainmed Medical Limited 潤 邁 德 醫 療 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：2297） 截 至 2023 年 6 月 30 日 止 六 個 月 之 中 期 業 績 公 告 財務摘要 未經審核 截至6月30日止六個月 2023年 2022年 變化 人民幣百萬元 人民幣百萬元 （百分比除外）（百分比除外） 收入 50.4 51.9 (2.9%) 毛利 37.3 44.8 (16.7%) 毛利率 74.0% 86.4% 本公司股東之應佔虧損 (47.5) (1,210.2) (96.1%) 經調整非香港財務報告準則之 本公司股東之應佔虧損附註 (42.1) (22.2) 89.6% ...

Financial Performance - Revenue for the year ended December 31, 2022, was RMB 83.6 million, representing a 3.0% increase from RMB 81.2 million in 2021[11] - Gross profit for 2022 was RMB 69.8 million, with a gross margin of 83.5%, down from 85.0% in 2021[11] - The company reported a loss attributable to shareholders of RMB 1,346.0 million, a 112.4% increase compared to a loss of RMB 633.6 million in 2021[11] - The adjusted loss per share for 2022 was RMB 0.11, an increase of 37.5% from RMB 0.08 in 2021[11] - Total revenue for the year ended December 31, 2022, was RMB 83.6 million, a slight increase from RMB 81.2 million in 2021, driven primarily by sales of the FlashPressure caFFR pressure sensor[46] - Gross profit increased from RMB 69.0 million in 2021 to RMB 69.8 million in 2022, with a gross margin of 83.5% in 2022 compared to 85.0% in 2021[47] - Research and development expenses surged by approximately 63.8% from RMB 27.0 million in 2021 to RMB 44.2 million in 2022, mainly due to increased employee benefits and professional service costs[49] - Sales expenses decreased by about 4.8% from RMB 70.1 million in 2021 to RMB 66.8 million in 2022, primarily due to a reduction in one-time share-based payment expenses[52] - General and administrative expenses decreased from RMB 115.2 million in 2021 to RMB 109.3 million in 2022, a year-on-year decline of approximately 5.1%[55] - Other income rose from RMB 0.4 million in 2021 to RMB 5.3 million in 2022, primarily due to an increase in government subsidies[56] - The net cash used in operating activities was RMB 111.2 million, mainly due to significant R&D, administrative, and sales expenses[60] - Cash and cash equivalents decreased from RMB 559.1 million in 2021 to RMB 91.1 million in 2022, a reduction of RMB 468.0 million[61] - The company recorded a loss of RMB 1,346.0 million for the year ended December 31, 2022, compared to a loss of RMB 633.6 million for the year ended December 31, 2021[59] - The fair value loss of financial liabilities increased significantly from RMB 493.9 million in 2021 to RMB 1,210.9 million in 2022 due to the rise in the company's valuation[58] Assets and Liabilities - Non-current assets increased by 34.6% to RMB 86,897,000 in 2022 from RMB 64,547,000 in 2021[13] - Total assets rose by 7.8% to RMB 690,330,000 in 2022 compared to RMB 640,192,000 in 2021[13] - Total liabilities decreased by 94.9% to RMB 71,694,000 in 2022 from RMB 1,414,676,000 in 2021[13] - Total equity improved significantly to RMB 618,636,000 in 2022 from a loss of RMB 774,484,000 in 2021, marking a change of 179.9%[13] Product Development and Market Position - The caFFR system achieved over 95% accuracy and a convenient operation time of less than five minutes, establishing a leading position in the domestic FFR measurement market[5] - The company plans to expand the indications for the caFFR system to include acute STEMI, acute NSTEMI, and HFpEF patients[5] - The caIMR system is expected to become the world's first commercially approved minimally invasive IMR measurement system in 2023[5] - The company aims to launch its vascular interventional surgical robot by 2024, integrating all clinical applications for automated PCI processes[5] - The caFFR system achieved a clinical accuracy rate of 93.81% in 2022, with over 1,000 hospitals using the system by year-end[17][19] - The caIMR system entered the special approval pathway of the National Medical Products Administration in April 2022, with commercialization expected in Q2 2023[17] - By the end of 2022, the caFFR system was commercialized in 30 provinces and regions in China, with 21 provinces covered by medical insurance[19] - The company is actively seeking investment and acquisition targets to enhance its product lineup and expand its precision diagnosis and treatment product lines[22] - The global FFR measurement market is projected to grow from approximately USD 504.1 million in 2020 to about USD 1,200.0 million by 2025, with a compound annual growth rate (CAGR) of 18.9%[26] - The Chinese FFR measurement market is expected to rise from RMB 78.6 million in 2020 to approximately RMB 2,385.7 million by 2025, reflecting a CAGR of 97.9%[26] Research and Development - The R&D team consists of over 100 members, accounting for approximately one-third of the total workforce, focusing on innovative products in the field of interventional precision therapy[34] - As of December 31, 2022, the company holds 102 approved patents and has 178 patents pending, including 129 in China and 49 overseas[34] - The company is considering investments and acquisitions within the industry to expand its product pipeline and introduce innovative products[23] - The IMR measurement market is still in its early stages, and the company plans to focus on training for doctors, patients, and hospital managers regarding the caIMR system[27] Corporate Governance and Management - The company has a management team with over 16 years of experience in compliance, investment, and financing, enhancing its strategic capabilities[83] - The company’s Vice President, Ms. Gu Yang, has been with the group since March 2021, focusing on human resources management[87] - The company’s independent non-executive director, Mr. Liao Chuanjiang, has over 20 years of experience in accounting, auditing, and management, providing independent oversight[94] - The company has a strong governance structure with a diverse board, including members with extensive backgrounds in finance and investment management[89][92] - The company is focused on compliance and regulatory communication, ensuring adherence to market standards[84] - The company’s strategic direction is supported by a board that provides investment strategies and governance guidance[89][92] Shareholder Information - As of December 31, 2022, Mr. Huo Yunfei holds 214,749,000 shares, representing 18.39% of the company[155] - Mr. Lü Yonghui holds 30,937,000 shares, accounting for 2.65% of the company[155] - The company has a total of 1,167,799,000 shares issued as of December 31, 2022[174] - The company has significant ownership concentration, with several shareholders holding around 5.05% each[171] - The ownership structure includes various partnerships and trusts, indicating a complex ownership arrangement[172] - The company is indirectly controlled by Ping An Group, which holds significant stakes in related investment entities[176] Future Outlook and Challenges - The company remains optimistic about the market outlook in mainland China and Hong Kong for 2023 despite recent challenges[45] - The group has faced significant operational losses since its inception, which may continue in the foreseeable future as it expands product development and seeks regulatory approvals[127] - Regulatory approval processes are lengthy, costly, and inherently unpredictable, which could severely impair the group's ability to commercialize its research products[137] - The group may face additional costs or delays in product development if clinical trials do not demonstrate satisfactory safety and efficacy to regulatory authorities[127] - The group’s future growth largely depends on the successful development and commercialization of its research products[127]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任 何責任。 Rainmed Medical Limited 潤 邁 德 醫 療 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：2297） 截 至 2022 年 12 月 31 日 止 年 度 之 年 度 業 績 公 告 財務摘要 截至12月31日止年度 2022年 2021年 變動 人民幣百萬元 人民幣百萬元 （百分比除外）（百分比除外） （經審核） （經審核） 收入 83.6 81.2 3.0% 毛利 69.8 69.0 1.2% 毛利率 83.5% 85.0% 本公司股東之應佔虧損 (1,346.0) (633.6) 112.4% 經調整非香港財務報告準則之 本公司股東之應佔虧損附註 (100.9) (51.7) 95.2% ...